The FDA oversees more than $2.8 trillion in consumer products through specialized centers — each with its own regulatory framework, submission pathways, and compliance requirements. This guide breaks down every major FDA center and what it means for your business.
Jared Clark, JD, MBA, PMP, CMQ-OE, RAC, CPGP, CFSQA
Cross-industry FDA expertise from Certify Consulting, our full-service certification and compliance practice.
The FDA regulates roughly 20 cents of every dollar spent by American consumers — but not through a single monolithic bureaucracy. Instead, the agency divides its jurisdiction across specialized product centers, each with its own statutory authority, compliance frameworks, and enforcement mechanisms.
Understanding which FDA center regulates your product is the first and most critical step in any compliance strategy. The center that claims jurisdiction determines everything: what regulations apply, which submission pathways are available, how your facility must be registered, what inspections you will face, and what enforcement actions the FDA can take if you fall out of compliance.
The four primary FDA product centers are CDER (Center for Drug Evaluation and Research), CDRH (Center for Devices and Radiological Health), CFSAN (Center for Food Safety and Applied Nutrition), and CBER (Center for Biologics Evaluation and Research). Each center has its own culture, its own regulatory philosophy, and its own set of expectations for the companies it oversees. A company accustomed to CDRH's device regulations will find the transition to CDER drug requirements genuinely disorienting — and vice versa.
What makes navigating this landscape particularly challenging is that many companies operate across multiple FDA centers. A pharmaceutical company launching a companion diagnostic device, a food manufacturer expanding into dietary supplements, or a biotech startup developing a drug-device combination product will find themselves answering to two or more centers simultaneously — each with different registration requirements, different GMP standards, and different pre-market submission expectations.
This is where specialized FDA consulting becomes essential. Most FDA consultants focus on a single center or product category. Jared Clark's practice at Certify Consulting spans the full scope of FDA jurisdiction, providing a rare breadth of regulatory expertise across drugs, devices, food, supplements, and biologics. Whether you are navigating your first FDA registration or managing ongoing compliance across multiple product lines, having a consultant who understands the regulatory landscape at the center level is a meaningful strategic advantage.
Select the FDA center that governs your product category
Prescription Drugs, OTC Drugs, Generic Drugs (ANDA)
CDER is the largest of FDA's product centers and regulates the broadest range of pharmaceutical products in the United States. If your company manufactures, distributes, repackages, or relabels any human drug product — whether a branded prescription drug, an over-the-counter (OTC) medication, or a generic pharmaceutical submitted through the Abbreviated New Drug Application (ANDA) pathway — CDER is your primary regulatory authority.
CDER's regulatory authority derives primarily from the Federal Food, Drug, and Cosmetic Act (FD&C Act) and is implemented through Title 21 of the Code of Federal Regulations (CFR). The center's mandate covers the entire drug lifecycle: from pre-clinical research and clinical trials through manufacturing, marketing, and post-market surveillance. The core regulatory frameworks that CDER-regulated companies must navigate include:
CDER compliance begins with facility registration and product listing, which must be completed before any drug product enters commercial distribution in the United States. Every manufacturing establishment — including contract manufacturers, contract testing laboratories, repackagers, and relabelers — must register with FDA annually between October 1 and December 31 and pay the applicable establishment registration fee.
Beyond registration, CDER-regulated facilities must maintain rigorous CGMP compliance. This means validated manufacturing processes, qualified equipment and utilities, controlled environments, comprehensive batch records, stability testing programs, and a fully functional quality system with documented procedures for deviations, CAPAs (Corrective and Preventive Actions), change controls, and annual product reviews. FDA inspectors evaluate all of these systems during routine inspections, and any deficiency can result in FDA Form 483 observations, warning letters, or consent decrees.
Relevant credential: Jared Clark holds the CPGP (Certified Pharmaceutical GMP Professional) certification from ASQ and the RAC (Regulatory Affairs Certification) with Pharmaceuticals specialty from RAPS — the two most directly relevant credentials for CDER consulting work.
Jurisdictional questions are more common than you think — especially for combination products, dietary supplements with drug claims, or medical devices with biological components. Let's clarify your regulatory pathway in a free consultation.
Class I/II/III Medical Devices, IVDs, Combination Products
CDRH regulates the medical device industry in the United States — an enormous sector encompassing everything from simple tongue depressors and adhesive bandages (Class I) to complex surgical robots, artificial hearts, and implantable neurostimulators (Class III). The center also oversees in vitro diagnostic devices (IVDs), radiation-emitting electronic products, and combination products where a device is the primary mode of action. If your product meets the FD&C Act's definition of a medical device, CDRH is where your regulatory journey begins.
CDRH's regulatory framework is built around a risk-based classification system that assigns every medical device to one of three regulatory classes, each with progressively stricter requirements:
All medical device manufacturers must complete FDA establishment registration and device listing before commercial distribution. This applies to domestic manufacturers, foreign manufacturers exporting to the U.S. (who must also designate a U.S. Agent), contract manufacturers, contract sterilizers, specification developers, and repackagers/relabelers. Registration must be renewed annually between October 1 and December 31, along with payment of the annual registration fee.
Manufacturing compliance is governed by the Quality System Regulation (QSR) under 21 CFR Part 820, which requires device manufacturers to establish and maintain a comprehensive quality management system. Key QSR elements include design controls (for Class II and III devices), production and process controls, purchasing controls, corrective and preventive action (CAPA) systems, document controls, and management responsibility. The QSR is structurally similar to ISO 13485 (Quality Management Systems for Medical Devices), and many manufacturers pursue dual compliance to serve both U.S. and international markets.
For companies pursuing 510(k) clearance, the pre-market submission must demonstrate that the device is substantially equivalent to a legally marketed predicate device in terms of intended use, technological characteristics, and performance. This typically requires bench testing, biocompatibility testing (per ISO 10993), software validation (for software-containing devices), electrical safety testing (per IEC 60601 for electromedical devices), and clinical data when technological differences raise new questions of safety or effectiveness.
Combination products alert: If your product combines a device with a drug or biologic component (e.g., drug-eluting stents, pre-filled syringes, antimicrobial wound dressings), FDA's Office of Combination Products will assign a lead center based on the product's primary mode of action. This determination drives which regulatory pathway applies — and getting it wrong can add months or years to your timeline.
Conventional Food, Dietary Supplements, Infant Formula, Food Contact Substances
CFSAN regulates the safety and labeling of the vast majority of the U.S. food supply — everything except meat, poultry, and certain egg products, which fall under USDA jurisdiction. The center's regulatory scope includes conventional food products, dietary supplements, infant formula, food additives, color additives, food contact substances (food packaging materials), cosmetics, and bottled water. If your company manufactures, processes, packs, or holds food products for human consumption in the United States, CFSAN is your regulatory authority.
CFSAN's regulatory landscape was fundamentally reshaped by the Food Safety Modernization Act (FSMA), signed into law in 2011 and phased in through 2018. FSMA shifted the FDA's approach from reactive (responding to outbreaks after they occur) to preventive (requiring food facilities to identify and control hazards before they cause harm). The key regulatory frameworks governing CFSAN-regulated industries include:
CFSAN compliance starts with food facility registration, which is required before any food product can be commercially distributed in the United States. Foreign facilities must designate a U.S. Agent, and all registrations must be renewed biennially during even-numbered years between October 1 and December 31. While there is no FDA fee for food facility registration itself, the compliance infrastructure required to meet FSMA and CGMP standards represents a significant operational investment.
For conventional food manufacturers, FSMA's Preventive Controls rule is the central compliance requirement. This means developing and implementing a written food safety plan that includes a hazard analysis identifying known or reasonably foreseeable biological, chemical (including radiological), and physical hazards; preventive controls to significantly minimize or prevent those hazards; a supply-chain program for raw materials where the supplier controls the hazard; a recall plan; and monitoring, corrective action, and verification procedures. The plan must be developed or overseen by a Preventive Controls Qualified Individual (PCQI).
Dietary supplement manufacturers face a distinct set of CGMP requirements under 21 CFR Part 111. These regulations require identity testing of every incoming component (not just a certificate of analysis from the supplier), validated manufacturing processes, comprehensive batch production records, and a quality control operation that is independent from production. FDA has been increasingly aggressive in its enforcement of supplement CGMP violations, and warning letters in this space frequently cite failures in identity testing, batch record documentation, and complaint handling.
Relevant credential: Jared Clark holds the CFSQA (Certified Food Safety & Quality Auditor) certification from ASQ, validating auditing competence across food safety management systems including FSMA, HACCP, HARPC, and dietary supplement CGMP under 21 CFR Part 111.
Biologics, Blood Products, Vaccines, Gene Therapy
CBER regulates biological products — a category of therapeutic products derived from living organisms, including vaccines, blood and blood components, allergenic extracts, human tissues and cellular products, gene therapy products, and certain related devices and companion diagnostics. CBER-regulated products represent some of the most scientifically complex and heavily regulated items in the FDA's jurisdiction, and the regulatory standards reflect that complexity.
CBER derives its authority from both the FD&C Act and the Public Health Service (PHS) Act, giving it a dual statutory foundation that distinguishes it from the other product centers. The Biologics License Application (BLA) is the primary pre-market submission pathway for biological products, analogous to the NDA for drugs but with additional requirements reflecting the unique manufacturing and characterization challenges of biologics. Key regulatory frameworks include:
CBER-regulated facilities must meet the highest tier of FDA manufacturing standards. Establishment registration is required for all biologics manufacturers, and the registration process is tied directly to the biologics licensing framework — meaning that manufacturing changes may require BLA supplements and FDA approval before implementation. This is a fundamental difference from the device world, where manufacturers have more flexibility to make manufacturing changes under their quality system.
Manufacturing compliance for biologics requires validated aseptic processing, extensive environmental monitoring programs, robust contamination control strategies, raw material qualification (including characterization of biological source materials), in-process testing at critical control points, and comprehensive lot release testing. Many biological products also require potency assays — biological tests that measure the product's functional activity — which must be validated and maintained throughout the product lifecycle.
The regulatory landscape for CBER products has been evolving rapidly, particularly in the areas of cell and gene therapy. The FDA has published numerous guidance documents addressing manufacturing requirements for regenerative medicine products, including expectations for chemistry, manufacturing, and controls (CMC) information in IND and BLA submissions. Companies developing advanced therapy medicinal products (ATMPs) face unique regulatory challenges around potency testing, comparability studies for manufacturing changes, and long-term patient follow-up requirements.
Cross-center considerations: Many CBER-regulated products involve device components (e.g., cell separation devices, diagnostic companion tests, delivery devices for gene therapy vectors). These combination products require coordination between CBER and CDRH, and the regulatory strategy must address both centers' requirements. Jared's cross-center expertise is particularly valuable in these complex jurisdictional scenarios.
Most FDA consultants specialize in one center. Jared Clark's practice spans all four — and that distinction matters more than you might think.
The FDA is not one agency — it's effectively four regulatory agencies under one roof, each with its own culture, its own expectations, and its own enforcement priorities. A pharmaceutical consultant who has spent their entire career in CDER may not fully understand the design control requirements that are central to CDRH compliance. A device consultant may not appreciate the nuances of FSMA's preventive controls framework. And almost no one outside the biologics world truly understands the complexity of CBER's lot release and potency testing requirements.
This siloed expertise creates real problems for companies whose products or operations cross center boundaries. Consider these common scenarios:
In each of these scenarios, having a single consultant who understands both regulatory frameworks — and can build a compliance strategy that satisfies both centers — eliminates the coordination problems, conflicting advice, and knowledge gaps that arise when companies try to manage multi-center compliance with center-specific consultants.
RAC (Regulatory Affairs Certification) with Pharmaceuticals specialty plus CPGP (Certified Pharmaceutical GMP Professional) — directly relevant to CDER and CBER consulting, with device regulatory expertise spanning all three device classes.
CFSQA (Certified Food Safety & Quality Auditor) validates auditing competence across FSMA, HACCP, HARPC, and dietary supplement CGMP. Combined with JD credentials, this enables both compliance and legal analysis of CFSAN regulatory requirements.
Regardless of which FDA center regulates your product, we provide end-to-end consulting services from initial registration through ongoing compliance management.
Facility registration and product listing across all FDA centers — drugs, devices, food, supplements, biologics. Domestic and foreign manufacturers.
Pre-market notification strategy, predicate device selection, testing protocols, submission preparation, and FDA correspondence management.
Quality system development, CGMP implementation, SOP documentation, audit programs, and ongoing compliance monitoring across all product categories.
Mock inspections, readiness assessments, staff training, and documentation review to ensure your facility is prepared for FDA investigators.
Response strategy, corrective action plans, CAPA implementation, and FDA follow-up management for warning letters across all product categories.
Real-world examples of how we've helped companies across drugs, devices, food, and supplements navigate FDA challenges and achieve compliance.
Whether you manufacture drugs, medical devices, food products, dietary supplements, or biologics — or a combination that spans multiple FDA centers — we can help you navigate the regulatory landscape. Schedule a free consultation with Jared Clark, RAC, to discuss your specific compliance needs.